MedTrace Logo

A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Atopic Dermatitis

NCT02424253 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 98

Last updated 2021-06-10

Study results available
· View outcomes & findings →

Summary

This was a randomized, double blind, placebo controlled, parallel group study in approximately 90 subjects with moderate-severe AD Eczema Area and Severity Index (EASI) ≥12 and ≤ 48 (0-72 scale). Following a run-in subjects were randomized to receive either oral 30 mg ZPL-3893787 once daily (od) or placebo od for 8 weeks (56 days).

Conditions

Interventions

DRUG

ZPL-3893787

ZPL-3893787

DRUG

Placebo

Matched Placebo

Sponsors & Collaborators

  • Ziarco Pharma Ltd

    lead INDUSTRY

Principal Investigators

  • Study Director · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-18
Primary Completion
2016-01-31
Completion
2016-02-03

Countries

  • Belgium
  • Germany
  • Poland
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02424253 on ClinicalTrials.gov